Intra-operative electron beam radiotherapy and abdomino-pelvic surgery for cancer: influence on immunological parameters.
Evolution of some immunological parameters was observed during the first month in 20 patients with different abdomino-pelvic cancers who underwent surgery with intra-operative radiation therapy (IORT) (mean dose of 19.44 Gy, range 15, 25). Observed parameters before (DO-) and after procedure (DO+), on seventh (D7) and fourteenth (D14) days and fifth week (D30) were: lymphocyte count, lymphocyte subsets (CD19, CD3, CD4, CD8, CD56), natural killer (NK) activity, immunoglobulins, C3 and C4b fractions of complement, soluble receptor for interleukin 2 (sIL2-R). Results showed a decrease of circulating lymphocytes (DO-: 1189 +/- 168 cells/mm3; D7: 889 +/- 91; P = 0.011), of absolute number of CD3 lymphocytes (DO-: 785 +/- 114 cells/mm3; D7: 563 +/- 86; P = 0.025), of CD4 lymphocytes (DO-: 441 +/- 70 cells/mm3; DO+: 299 +/- 43; P = 0.013) and of CD8 lymphocytes (DO-:361 +/- 50 cells/mm3, D7:250 +/- 44; P = 0.006). All values returned towards preoperative levels by D30. Absolute number of NK cells was unchanged but NK activity was significantly diminished (effector target ratio 5:1 DO-:33 +/- 5%; DO+:44 +/- 7%; D7:18 +/- 3%; D14:21 +/- 4%; D30:25 +/- 4%). sIL2-R was significantly enhanced from D7 to D30. All these impairments are moderate and these observations provide some evidence of satisfactory tolerance to IORT for abdomino-pelvic cancers during the immediate postoperative period.
Bussières
E
E
Department of Surgery, Fondation Bergonié, Bordeaux, France.
Richaud
P
P
Gualde
N
N
D000008:Abdominal Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic / Q000528:radiation effects; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000528:radiation effects; D007430:Intraoperative Care; D007694:Killer Cells, Natural / Q000276:immunology / Q000528:radiation effects; D016131:Lymphocyte Subsets / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000601:surgery; D011184:Postoperative Period; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D012995:Solubility
D015375:Receptors, Interleukin-2